A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
Coherus Oncology, Inc.
Myeloid Therapeutics
Normunity AccelCo, Inc.
Memorial Sloan Kettering Cancer Center
Prelude Therapeutics
Kyowa Kirin Co., Ltd.
IDEAYA Biosciences
Plexium, Inc.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Seagen Inc.
Pfizer
NeoTX Therapeutics Ltd.
Blueprint Medicines Corporation
Arbele Limited
National Cancer Institute (NCI)
Inhibrx Biosciences, Inc
University of Oxford
MacroGenics
Wake Forest University Health Sciences
Roswell Park Cancer Institute
University of Michigan
Merck KGaA, Darmstadt, Germany
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
Case Comprehensive Cancer Center
Christiana Care Health Services